Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01958580 · ClinicalTrials.gov registry record · NA
Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery
A NA study, sponsored by Albert Einstein College of Medicine.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT01958580: Clinical Trial NA study, sponsored by Albert Einstein College of Medicine.
NCT01958580 is a NA study that was terminated before completion, run by Albert Einstein College of Medicine. The registered enrollment target is 3 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01958580, a NA study, was terminated before completion, sponsored by Albert Einstein College of Medicine.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
This pilot clinical trial studies gemcitabine hydrochloride, docetaxel, and radiation therapy in treating patients with uterine sarcoma that has been removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride and docetaxel, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x rays to kill tumor cells. Giving combination chemotherapy with radiation therapy may kill any tumor cells that remain after surgery.
Primary Outcome
Two-year recurrence-free survival probability will be estimated, with 95% confidence limits based on exact methods for the binomial distribution. In the event of censoring before two years, a Kaplan-Meier estimate of the survival probability will be used and a Kaplan-Meier survival curve will be estimated and presented as well. The study was terminated prior to analyses
Interventions
- DRUG Docetaxel
- RADIATION External Beam Radiation Therapy
- RADIATION Intensity-Modulated Radiation Therapy
- DRUG Gemcitabine Hydrochloride
- RADIATION Internal Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2013-09-17 |
| Est. Completion | 2017-02-24 |
| Phase | NA |
Why NCT01958580 stopped before completion
NCT01958580 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT01958580 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01958580 about?
NCT01958580 is a clinical study titled "Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery". This pilot clinical trial studies gemcitabine hydrochloride, docetaxel, and radiation therapy in treating patients with uterine sarcoma that has been removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride and docetaxel, work in different ways to stop the growth of cancer c...
What is the current status of trial NCT01958580?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2013-09-17. Estimated completion is 2017-02-24.
What interventions are being tested in trial NCT01958580?
The interventions under investigation include: Docetaxel (DRUG), External Beam Radiation Therapy (RADIATION), Intensity-Modulated Radiation Therapy (RADIATION), Gemcitabine Hydrochloride (DRUG), Internal Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT01958580?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01958580's enrollment target sits among peer trials
3 1996th of 2000 higher than 4 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI